Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 is a research paper published in Cell Host & Microbe (2020). On theSindex it has a DataRank of 0. It has been cited 486 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Helen Hay Whitney Foundation
Grant: MA104
National Institutes of Health
Grant: 75N93019C00062
National Institutes of Health
Grant: HHSN272201700060C
National Institutes of Health
Grant: R01 AI127828
National Institutes of Health
Grant: R37 AI059371
National Institutes of Health
Grant: U01 AI151810
Defense Advanced Research Projects Agency
Grant: HR001117S0019
NIAID NIH HHS
Grant: R01 AI150796
NIAID NIH HHS
Grant: R00 AI135031
National Institutes of Health
Grant: 5R01AI127828-05
Human neutralizing antibodies for Zika virus
National Institutes of Health
Grant: 3U01AI151810-03S1
Emerging infections: surveillance, epidemiology and pathogenesis
National Institutes of Health
Grant: 5R37AI059371-15
RNA Processing in Non-Segmented Minus-Strand RNA Viruses
Washington University School of Medicine in St. Louis
Washington University in St. Louis
Eli Lilly and Company
Vir Biotechnology
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 3 of Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
Additional file 3 of Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
Additional file 1 of Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
Additional file 1 of Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
Additional file 2 of Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
Additional file 2 of Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
Additional file 1 of Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
Additional file 1 of Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
Additional file 1 of Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron
Additional file 1 of Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron